1058 related articles for article (PubMed ID: 7755915)
1. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Odeke R; Madra P; Hitimana-Lukanika C; Adatu-Engwau F; Blandford JM
Int J Tuberc Lung Dis; 2007 Jul; 11(7):747-54. PubMed ID: 17609049
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Hitimana-Lukanika C; Odeke R; Madra P; Adatu F; Blandford JM
Int J Tuberc Lung Dis; 2006 Jun; 10(6):656-62. PubMed ID: 16776453
[TBL] [Abstract][Full Text] [Related]
4. Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda.
Lugada ES; Watera C; Nakiyingi J; Elliott A; Brink A; Nanyunja M; French N; Antivelink L; Gilks C; Whitworth J
Int J Tuberc Lung Dis; 2002 Apr; 6(4):326-31. PubMed ID: 11936742
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda.
Mugisha B; Bock N; Mermin J; Odeke RM; Miller B; Adatu-Engwau F; Granich R; Bunnell R
Int J Tuberc Lung Dis; 2006 Jul; 10(7):761-7. PubMed ID: 16848338
[TBL] [Abstract][Full Text] [Related]
6. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Sutton BS; Arias MS; Chheng P; Eang MT; Kimerling ME
Int J Tuberc Lung Dis; 2009 Jun; 13(6):713-8. PubMed ID: 19460246
[TBL] [Abstract][Full Text] [Related]
7. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
Hawken MP; Muhindi DW
Int J Tuberc Lung Dis; 1999 Aug; 3(8):646-50. PubMed ID: 10460096
[TBL] [Abstract][Full Text] [Related]
9. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
Namuwenge PM; Mukonzo JK; Kiwanuka N; Wanyenze R; Byaruhanga R; Bissell K; Zachariah R
Trans R Soc Trop Med Hyg; 2012 Feb; 106(2):84-9. PubMed ID: 22154974
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
[TBL] [Abstract][Full Text] [Related]
11. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Munseri PJ; Talbot EA; Mtei L; Fordham von Reyn C
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1037-41. PubMed ID: 18713501
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
[TBL] [Abstract][Full Text] [Related]
13. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration.
Johnson JL; Nyole S; Okwera A; Whalen CC; Nsubuga P; Pekovic V; Huebner R; Wallis RS; Mugyenyi PN; Mugerwa RD; Ellner JJ
Am J Respir Crit Care Med; 1998 Dec; 158(6):1790-6. PubMed ID: 9847269
[TBL] [Abstract][Full Text] [Related]
14. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
15. [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries].
Anglaret X; Dabis F; Batungwanayo J; Perronne C; Taelman H; Bonard D; Sylla-Koko F; Leroy V; Van de Perre P; Vildé JL; Salamon R
Sante; 1997; 7(2):89-94. PubMed ID: 9273126
[TBL] [Abstract][Full Text] [Related]
16. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
Foster S; Godfrey-Faussett P; Porter J
AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Sterling TR; Brehm WT; Moore RD; Chaisson RE
Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
[TBL] [Abstract][Full Text] [Related]
18. Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa.
Nuwaha F
East Afr Med J; 1998 Sep; 75(9):520-7. PubMed ID: 10493054
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
